[go: up one dir, main page]

KR880013556A - Uses of Dopamine Receptor Agonists - Google Patents

Uses of Dopamine Receptor Agonists Download PDF

Info

Publication number
KR880013556A
KR880013556A KR1019880005250A KR880005250A KR880013556A KR 880013556 A KR880013556 A KR 880013556A KR 1019880005250 A KR1019880005250 A KR 1019880005250A KR 880005250 A KR880005250 A KR 880005250A KR 880013556 A KR880013556 A KR 880013556A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
dopamine receptor
nicotine addiction
receptor agonist
composition according
Prior art date
Application number
KR1019880005250A
Other languages
Korean (ko)
Inventor
스털링 뮐러 페터
Original Assignee
쟝 크래머, 한스 루돌프 하우스
산도즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 쟝 크래머, 한스 루돌프 하우스, 산도즈 리미티드 filed Critical 쟝 크래머, 한스 루돌프 하우스
Publication of KR880013556A publication Critical patent/KR880013556A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

내용 없음No content

Description

도파민수용체 효능제의 용도Uses of Dopamine Receptor Agonists

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (8)

유효량의 직접 도파민수용체효능제(dopamine receptor agonist)를 니코틴중독치료가 필요한 환자에게 투여함을 특징으로 하여, 환자의 니코틴중독을 치료하는 방법.An effective amount of direct dopamine receptor agonist is administered to a patient in need of nicotine addiction treatment, thereby treating nicotine addiction in the patient. 니코틴중독을 치료하기 위한 직접 도파민수용체효능제의 용도.Use of direct dopamine receptor agonists to treat nicotine addiction. 니코틴중독치료용 약제학적조성물을 제조하기 위한 직접 도파민수용체효능제의 용도.Use of a direct dopamine receptor agonist to prepare a pharmaceutical composition for treating nicotine addiction. 활성제로서 직접 도파민수용체효능제를 혼입시킨, 니코틴중독치료용 약제학적조성물.A pharmaceutical composition for treating nicotine addiction, in which a dopamine receptor agonist is directly incorporated as an active agent. 제4항에 있어서, 담배소비량억제용 약제학적조성물.The pharmaceutical composition of claim 4, wherein the tobacco composition is suppressed. 제5항에 있어서, 담배를 끊거나 줄이기 위한 약제학적조성물.6. A pharmaceutical composition according to claim 5 for stopping or reducing tobacco. 제4항에 있어서, 활성제가 유리염기형태 또는 약제학적으로 허용되는 산부가염형태의 브로모크립틴인 약제학적조성물The pharmaceutical composition according to claim 4, wherein the active agent is bromocriptine in free base form or in pharmaceutically acceptable acid addition salt form. 제7항에 있어서, 유리염기형태 또는 약제학적으로 허용되는 산부가염형태의 브로모크립틴을 단위용량당 0.5 내지 2.5mg함유하는 약제학적조성물8. A pharmaceutical composition according to claim 7, which contains 0.5 to 2.5 mg per unit dose of bromocriptine in free or pharmaceutically acceptable acid addition salt form. ※ 참고사항 : 최초출원내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019880005250A 1987-05-07 1988-05-06 Uses of Dopamine Receptor Agonists KR880013556A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4775387A 1987-05-07 1987-05-07
US07/047,753 1987-05-07

Publications (1)

Publication Number Publication Date
KR880013556A true KR880013556A (en) 1988-12-21

Family

ID=21950776

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880005250A KR880013556A (en) 1987-05-07 1988-05-06 Uses of Dopamine Receptor Agonists

Country Status (13)

Country Link
JP (1) JPS63287723A (en)
KR (1) KR880013556A (en)
AU (1) AU622614B2 (en)
CH (1) CH675834A5 (en)
DE (1) DE3814521A1 (en)
DK (1) DK245388A (en)
FR (1) FR2614789B1 (en)
GB (1) GB2204240B (en)
IT (1) IT1219564B (en)
NL (1) NL8801171A (en)
PH (1) PH25495A (en)
SE (1) SE8801708L (en)
ZA (1) ZA883237B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797405A (en) * 1987-10-26 1989-01-10 Eli Lilly And Company Stabilized pergolide compositions
DE19626621A1 (en) * 1996-07-02 1998-01-08 Hexal Ag Plaster for transdermal application of pergolide
US6623752B1 (en) 1996-07-02 2003-09-23 Hexal Ag Patch for transdermal application for pergolid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR861128B (en) * 1985-05-06 1986-08-26 Sandoz Ag New use of dopamine agonists
DE3722383A1 (en) * 1986-07-14 1988-01-28 Sandoz Ag NEW USE OF BROMOCRIPTIN

Also Published As

Publication number Publication date
GB2204240A (en) 1988-11-09
SE8801708D0 (en) 1988-05-05
GB8810509D0 (en) 1988-06-08
DK245388A (en) 1988-11-08
GB2204240B (en) 1991-04-24
FR2614789A1 (en) 1988-11-10
NL8801171A (en) 1988-12-01
AU622614B2 (en) 1992-04-16
CH675834A5 (en) 1990-11-15
PH25495A (en) 1991-07-24
DK245388D0 (en) 1988-05-05
SE8801708L (en) 1988-11-08
JPS63287723A (en) 1988-11-24
DE3814521A1 (en) 1988-11-17
ZA883237B (en) 1990-01-31
IT8847906A0 (en) 1988-05-03
IT1219564B (en) 1990-05-18
FR2614789B1 (en) 1991-10-18
AU1560588A (en) 1988-11-10

Similar Documents

Publication Publication Date Title
ES2164040T1 (en) USE OF AGONISTS OF THE GLICINE UNION SITE OR INHIBITORS OF GLYCIN ABSORPTION FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS.
KR900701282A (en) Treatment, prevention of ischemic diseases of the heart or brain
KR920702216A (en) Use of Acetyl D-Carnitine in Glaucoma Treatment
KR900700089A (en) Pharmaceutical Compositions for Systemic Skin Permeable Administration
KR970009799A (en) Treatment of substance abuse withdrawal
KR930702000A (en) Use of parosetin for the treatment of old age dementia, edema, migraine headaches, or poor food
KR880002515A (en) Fast absorbing and acting sullindac or a mixture of sodium sullindak and base
KR920703041A (en) Ingredients and methods used to treat inflammatory or allergic diseases with pain
CA2270955A1 (en) Pharmaceutical composition containing morphinan derivative for treating drug dependence
KR970025615A (en) Cancer metastasis inhibitor
WO2002034267A8 (en) Combination of a transdermal therapeutic system and an oral and/or parenteral preparation containing dopamine agonists for the treatment of dopaminergic disease states
KR880007073A (en) medicine
KR900016135A (en) 4-Quinoline Carboxylic Acid Derivatives for the Treatment of Diseases of the Skin and Mucous-Epithelium
KR830002510A (en) Composition consisting of biologically active compound and hydroxyalkyl starch
BR0211855A (en) Drug and method for treating and improving restorative sleep quality
KR950701922A (en) Sulfate salts of substituted triazoles, pharmaceutical compositions comprising them and their compositions in therapies
KR880013556A (en) Uses of Dopamine Receptor Agonists
KR970701191A (en) Heterocyclic compounds
MX9203361A (en) PHARMACEUTICAL COMPOSITIONS CONTAINING GALIUM CHLORIDE.
KR920702225A (en) Pharmaceutical composition
US4476115A (en) Analgesic composition and method of treating subdermal pain
KR880004810A (en) Peptic Ulcer Treatment
KR890007728A (en) Painkiller
KR900017599A (en) Pharmaceutical composition for tumor treatment
KR890012961A (en) N- (lower alkyl) -2- (3'-ureidobenzyl) pyrrolidine

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19880506

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19930506

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19880506

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19961007

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 19970210

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 19961007

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I